Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
Definition
Biotechnology research firms fail to submit required clinical trial registration, results, or certifications to ClinicalTrials.gov, or submit false/misleading data, triggering FDA enforcement. The FDA issues a Notice of Noncompliance with 30 days to remedy; uncorrected violations lead to escalating daily penalties. This is systemic for biotech sponsors of applicable clinical trials involving drugs, biologics, or devices, especially high-risk trials for serious diseases.
Key Findings
- Financial Impact: $10,000 per day per violation
- Frequency: Daily (ongoing until corrected)
- Root Cause: Failure to comply with FDAAA requirements under 42 U.S.C. 282(j), often due to inadequate bioresearch monitoring, poor data management in biosafety/compliance workflows, or patterns of prior noncompliance detected via FDA inspections/complaints.
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Clinical Trial Sponsors, Regulatory Affairs Managers, Compliance Officers, Bioresearch Monitors
Deep Analysis (Premium)
Financial Impact
$10,000-$13,237 per day × 30-90 days = $300,000-$1,000,000+ per incident; multiple concurrent penalties across portfolio • $10,000-$13,237 per day per portfolio company trial; potential down-round due to regulatory headwinds; LP confidence erosion; fundraising impact • $10,000-$13,237 per day per trial in civil penalties; $300,000-$397,100 per month if 1 trial non-compliant for 30 days; escalates if multiple trials affected
Current Workarounds
Administrator manually checks eRA Commons; email escalation to research office; no automated risk flag; reliance on PI/coordinator responsiveness • Budget reallocation from research funds; emergency cost center corrections; no advance planning; CFO surprise • Compliance staff and study teams manually track which trials are FDAAA 801–applicable and which datasets, biosafety conditions, and result summaries are due to ClinicalTrials.gov using Excel trackers, email threads, SharePoint folders, calendar reminders, and individual memory instead of an integrated compliance system tied to protocol/biosafety approvals and trial milestones.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
- https://www.loeb.com/en/insights/publications/2020/08/final-fda-guidance-on-civil-money-penalties-relating-to-the-clinicaltrialsgov-data-bank
- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-relating-clinicaltrialsgov-data-bank
- https://www.healthlawupdate.com/blogs/are-you-complying-with-clinicaltrials-gov-reporting-obligations/
Related Business Risks
Protocol Approval Delays Driving Trial Start-Up Time Drag
Publish-or-Perish Conflicts with Patent Timing
High IRB/Ethics Committee Fees and Site Activation Delays
Idle Resources from Protocol Amendment Cycle Times
Excessive Protocol Amendments in Research Protocol Development
Administrative Delays in Licensing Contracts
Request Deep Analysis
🇺🇸 Be first to access this market's intelligence